Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FIDELIO: Enfortumab Vedotin Plus Pembrolizumab for Bladder-Sparing in Urothelial Bladder Cancer
NCT07663747Phase 2Not yet recruiting
- Sponsor
- Netherlands Cancer Institute
- Start
- Sep 2026
- Primary completion
- Apr 2031
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of enfortumab vedotin and pembrolizumab in Urothelial Bladder Cancer (UBC) (4 arms), sponsored by Netherlands Cancer Institute. Primary endpoint: Bladder-intact event-free survival at 2 years. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
enfortumab vedotinpembrolizumab
03
Conditions
Urothelial Bladder Cancer (UBC)
Beyond the preview
Go deeper on NCT07663747.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07663747.